Molbio Diagnostics Limited
NSE: MOLBIOMedical Equipment & Supplies
Share price
₹1,479.20
-4.24% close of 8 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 5 Oct 2026, the close above is 8 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
62
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹16,271 Cr
P/E ratio
97.4
P/B ratio
—
ROCE
18.5%
ROE
15.6%
Dividend yield
0.0%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Our sales figures for this company step up at Mar 2026 and we hold nothing that says why, so we cannot honestly quote a growth rate across it.
Whether it grew faster than its sector
Our sales figures for this company step up at Mar 2026 and we hold nothing that says why, so there is no honest growth rate of its own to set against its sector.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
It has no steady three-year profit record yet, so growth cannot be weighed against the price.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Molbio Diagnostics Limited — this one | — | 97.4× | — |
| Poly Medicure Limited | 15%/yr | 51.2× | ₹3.4 |
| Fischer Medical Ventures Limited | 831%/yr | 84.9× | — |
| Tarsons Products Limited | — | 150.2× | — |
| Laxmi Dental Limited | 124%/yr | 30.4× | — |
| QMS Medical Allied Services Limited | — | 34.0× | — |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Medical Equipment & Supplies), it ranks 1 of 8 on returns, 3 of 8 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
A narrow advantage: it earns 18.5% on capital, ahead of 88% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the 3 years of cash statements on file it made ₹347 crore of cash from the business and spent ₹121 crore on plant and equipment, with ₹226 crore to spare; it still raised ₹218 crore mostly borrowed — borrowings rose from ₹184 crore to ₹450 crore.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
6 of 7 checks clear · 86%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Announced 5 Sep 2026 · Consolidated · Unaudited
Revenue
₹408 Cr
Net profit
₹53 Cr
Net margin
12.9%
EPS
₹5.21
Earnings call transcript · 8 Sep 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹16,271 Cr
- Prev close
- ₹1,479.20
- 52w High
- ₹1,687
- 52w Low
- ₹926
- Enterprise value
- ₹17,130 Cr
- Beta
- —
- Price CAGR 1y
- —
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 7.8%
- PEG ratio
- —
- P/E ratio
- 97.4
- P/B ratio
- —
- EV / EBITDA
- 54.7
- Industry P/E
- 59.5
- ROCE
- 18.5%
- ROCE 5y average
- 19.5%
- ROE
- 15.6%
- Debt / Equity
- 0.4
- Interest coverage
- 8.0
- Dividend yield
- 0.0%
- ROE 3y average
- 16.0%
- ROE last year
- 16.0%
Annual P&L
- Annual revenue
- ₹1,446 Cr
- Annual profit
- ₹164 Cr
- Operating margin
- 22.0%
- Net profit margin
- 11.3%
- EBITDA margin
- 22.1%
- Sales growth 3y
- —
- Sales growth 5y
- —
- Profit growth 3y
- —
- Profit growth 5y
- —
- EPS
- ₹14.8
- Sales growth TTM
- 42.0%
- Profit growth TTM
- 10.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- ₹408 Cr
- Profit latest quarter
- ₹53 Cr
- YoY quarterly sales growth
- 308.0%
- YoY quarterly profit growth
- —
- OPM latest quarter
- 25.0%
Balance Sheet
- Book Value
- ₹106
- Face Value
- ₹1.0
- Total debt
- ₹450 Cr
- Total cash
- ₹367 Cr
- Borrowings
- ₹450 Cr
- Reserves / Equity
- 105.3
Cash Flow
- Operating cash flow
- ₹50 Cr
- Free cash flow
- ₹1 Cr
- FCF yield
- -0.2%
- Net cash flow
- ₹273 Cr
Shareholding
- Promoter holding
- 41.3%
- FII holding
- 1.5%
- DII holding
- 16.4%
- Public holding
- 40.8%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Molbio Diagnosti | 1,513.10 | 69.8 | 17,437 | 0.00 | 52.8 | 347.8 | 408.4 | 309.6 | 18.5 |
| Poly Medicure | 1,638.10 | 51.9 | 16,604 | 0.21 | 85.3 | -7.6 | 525.4 | 30.3 | 12.5 |
| Fischer Medical | 33.46 | 95.5 | 2,338 | 0.15 | 3.8 | -22.0 | 81.9 | 249.5 | 11.4 |
| Tarsons Products | 329.40 | 148.0 | 1,753 | 0.00 | -1.4 | -180.9 | 110.2 | 20.7 | 4.6 |
| Q-Line Biotech | 661.10 | 27.2 | 1,542 | 0.00 | 34.4 | 147.3 | 197.9 | -8.6 | 22.4 |
| Laxmi Dental | 193.87 | 30.7 | 1,067 | 0.00 | 10.3 | 22.8 | 74.7 | 13.9 | 15.1 |
| Hemant Surgical | 610.50 | 52.4 | 888 | 0.00 | 12.8 | 159.2 | 166.7 | 189.2 | 18.9 |
| Vasa Denticity | 459.00 | 65.8 | 796 | 0.00 | 4.2 | 46.0 | 82.2 | 36.9 | 7.5 |
| Median | 329.40 | 36.3 | 656 | 0.00 | 4.2 | 19.8 | 74.7 | 21.5 | 15.1 |
Competes with: Dhoot Transmission Limited, Dr. Lal Path Labs Ltd., Fischer Medical Ventures Limited, GKB Ophthalmics Limited, Laxmi Dental Limited, Metropolis Healthcare Limited, Nureca Limited, Poly Medicure Limited, QMS Medical Allied Services Limited, Tarsons Products Limited, Vijaya Diagnostic Centre Limited
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 100 | 561 | 408 |
| Expenses | 116 | 402 | 308 |
| Material Cost | 131 | ||
| Change in Inventories | 12 | ||
| Purchases of Stock-in-Trade | 6.26 | ||
| Employee Cost | 46 | ||
| Other Expenses | 112 | ||
| Operating Profit | -16 | 159 | 101 |
| OPM % | -16 | 28 | 25 |
| Other Income | 1 | 5 | 3 |
| Exceptional items (within Other Income) | 0 | ||
| Interest | 4 | 12 | 11 |
| Depreciation | 12 | 20 | 17 |
| Profit before tax | -31 | 132 | 76 |
| Tax % | -23 | 27 | 31 |
| Net Profit | -24 | 96 | 53 |
| EPS in Rs | -11 | 8.06 | 5.21 |
| Diluted EPS in Rs | 5.21 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 837 | 1,020 | 1,446 |
| Expenses | 602 | 760 | 1,126 |
| Operating Profit | 234 | 260 | 320 |
| OPM % | 28 | 26 | 22 |
| Other Income | -49 | -4 | 9 |
| Interest | 14 | 18 | 33 |
| Depreciation | 41 | 45 | 64 |
| Profit before tax | 130 | 194 | 231 |
| Tax % | 36 | 29 | 29 |
| Net Profit | 84 | 139 | 164 |
| EPS in Rs | 452 | 64 | 15 |
| Dividend Payout % | 0 | 0 | 0 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- —
- 3 years
- —
- TTM
- 42%
Compounded profit growth
- 10 years
- —
- 5 years
- —
- 3 years
- —
- TTM
- 10%
Return on equity
- 10 years
- —
- 5 years
- —
- 3 years
- 16%
- Last year
- 16%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 2 | 2 | 11 |
| Reserves | 821 | 966 | 1,158 |
| Borrowings | 184 | 147 | 450 |
| Other Liabilities | 211 | 346 | 496 |
| Total Liabilities | 1,218 | 1,461 | 2,115 |
| Fixed Assets | 289 | 290 | 536 |
| CWIP | 2 | 27 | 11 |
| Investments | 6 | 46 | 6 |
| Other Assets | 921 | 1,099 | 1,562 |
| Total Assets | 1,218 | 1,461 | 2,115 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from Operating Activity | 10 | 287 | 50 |
| Cash from Investing Activity | -45 | -123 | -54 |
| Cash from Financing Activity | -32 | -26 | 276 |
| Net Cash Flow | -67 | 138 | 273 |
| Free Cash Flow | -7 | 232 | 1 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debtor Days | 186 | 97 | 103 |
| Inventory Days | 338 | 384 | 285 |
| Days Payable | 101 | 203 | 126 |
| Cash Conversion Cycle | 423 | 278 | 261 |
| Working Capital Days | 200 | 128 | 116 |
| ROCE % | 21 | 18 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
exports as % of revenue
16.00pct
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
News
News and filings about Molbio Diagnostics Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Exports to
- Nigeria
Sells to
- Central Medical Services Society (CMSS) · TrueNat MTB Chips with Rif chips (Truenat MTB / MTB-RIF Dx test kits) for the National Tub…
Buys from
- UE LifeSciences · iBreastExam portable, radiation-free breast health screening device distributed/marketed b…
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Medical Equipment & Supplies
- Classification
- Healthcare › Medical Equipment & Supplies
- ISIN
- INE869T01028
Plants
- Bengaluru Unit - Machohalli (Prognosys Medical Systems) · Bengaluru, Karnataka
- Bengaluru Unit - Peenya · Bengaluru, Karnataka
- Goa Unit I · Goa, Goa
- Goa Unit II · Goa, Goa
- Visakhapatnam Unit · Visakhapatnam, Andhra Pradesh
News impact
Big market events that reach Molbio Diagnostics Limited, and how the effect spreads.
1 Oct, 10:45 IST · Market event · high impact
Motilal Oswal Alternates sells over 2% stake in Molbio Diagnostics for ₹306 cr
Motilal Oswal's fund sold a 2% Molbio Diagnostics stake for ₹306 crore, pressuring Molbio shares short-term while the fund and block buyers gain; labs, device peers and brokers are unaffected.
Who it hits first
- A Motilal Oswal Alternates fund sold 23.28 lakh Molbio Diagnostics shares, over 2%, for Rs 306 crore at Rs 1315.01 each.
- Molbio shares face near-term selling pressure as the market absorbs the extra supply.
- The selling fund locks in cash and a realized return it can report to investors and redeploy.
Who may gain
- Motilal Oswal Alternates fund investors, who get Rs 306 crore of realized cash back
- Institutions that bought the block, if they picked up Molbio shares at a discount to the market price
- No operating winner: demand for diagnostic tests and machines is unchanged by a share sale
Along the supply chain
Downstream
No downstream link: distributors, labs and hospitals buy diagnostic tests, not the fund's shares.
Upstream
No upstream supply link: a secondary share sale does not change what Molbio buys from parts or material makers.
Where demand moves
Business
No business demand shifts: hospitals and labs order the same Molbio machines and test cartridges the day after a shareholder sells stock.
Capital
Rs 306 crore of equity moves from the seller fund to block buyers; the fund books liquidity and eventual performance fees while Molbio shares digest the new supply.
How it spreads across sectors
Financial Services
Tiny and neutral for brokers: one Rs 306 crore fund realization does not move trading volumes or fees.
Healthcare
Neutral: a single-stock ownership change with no pricing, volume or policy readthrough to labs or device makers.
When it plays out
Immediate
Molbio stock wobbles for 1-7 days as the block supply settles and buyers are revealed.
Medium term
Within 1-6 months the episode fades; Molbio trades on test volumes and earnings, the fund on its next exits.
Short term
Over 1-4 weeks the price finds its level near the block price unless a big new holder keeps buying.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Bulk & block deals
| Date | Who | Bought / sold | Shares | Price |
|---|---|---|---|---|
| 16 Sep 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | SELL | 5,91,823 | ₹1,288.60 |
| 16 Sep 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | BUY | 5,90,709 | ₹1,288.14 |
| 11 Sep 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | BUY | 12,33,175 | ₹1,565.79 |
| 11 Sep 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | SELL | 12,28,332 | ₹1,566.94 |
| 11 Sep 2026 | QE SECURITIES LLP | BUY | 12,10,738 | ₹1,542.36 |
| 11 Sep 2026 | QE SECURITIES LLP | SELL | 11,88,458 | ₹1,552.02 |
| 11 Sep 2026 | MICROCURVES TRADING PRIVATE LIMITED | BUY | 7,53,493 | ₹1,544.97 |
| 11 Sep 2026 | MICROCURVES TRADING PRIVATE LIMITED | SELL | 7,53,493 | ₹1,545.88 |
| 11 Sep 2026 | HRTI PRIVATE LIMITED | BUY | 7,37,245 | ₹1,520.67 |
| 11 Sep 2026 | HRTI PRIVATE LIMITED | SELL | 6,01,018 | ₹1,547.45 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call · Q1FY278 Sep 2026
- Results presentation30 Jun 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.